Premium
Monitoring disease burden in chronic myeloid leukemia: Past, present, and future
Author(s) -
Egan Daniel,
Radich Jerald
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24381
Subject(s) - myeloid leukemia , medicine , disease , chronic disease , disease burden , intensive care medicine
Tyrosine kinase inhibitor (TKI) therapy yields sustained cytogenetic remissions in most patients with chronic‐phase chronic myeloid leukemia (CML). Peripheral blood quantitative reverse transcription polymerase chain reaction (qRT‐PCR) monitoring of the chimeric BCR‐ABL1 mRNA transcript levels is a very sensitive method to measure disease burden in patients with cytogenetic remission. qRT‐PCR allows identification of patients (1) at high risk of progression early (3–6 months) after treatment initiation, (2) with no response to TKI therapy, (3) with undetectable disease who could be eligible for TKI discontinuation trials. Molecular monitoring is a minimally invasive method to optimize treatment and outcomes in CML. Am. J. Hematol. 91:742–746, 2016. © 2016 Wiley Periodicals, Inc.